Neural ID, which provides biosignal analytics for the pharmaceutical industry, has teamed up with IDBS. The collaborative offering combines BioBook, IDBS’ electronic laboratory notebook for life sciences and Neural ID’s flagship product IWS which provides users with automated data analysis and data reporting.
For the first time BioBook users will have the ability to achieve full traceability and drill down capacity of the study lifecycle. This includes summary reports through study design and analysed data, down to processed instrumentation biosignals. The summary data reported into BioBook from IWS will be fully searchable. Users of IWS will be able to generate deep analytic value across cardio safety assessments from discovery all the way through clinical applications and support GxP regulated environments.
As part of the collaboration, the two companies presented the new approach to machine learning and scalable biosignal analytics during Bio-IT World in April 2014.
‘Researchers are keen to reduce study cycle times and accelerate decision making around the safety and efficacy of new products. We recognise the need for a consistent and reproducible way to automate waveform analysis throughout the drug discovery and development lifecycle,’ said Scott Weiss, Director, Product Strategy, IDBS. ‘Our collaboration with Neural ID addresses this critical need. The integration will eliminate manual data import, reducing transcription errors. It also provides improved user productivity with automated write-up and reporting.’
